A Single-arm, International, Prospective, Interventional, Open-label, Multicenter Study of Radium-223 Dichloride in the Treatment of Patients With Castration-Resistant Prostate Cancer (CRPC) With Bone Metastasis.
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Adenocarcinoma; Bone metastases; Prostate cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Bayer
- 27 Aug 2020 According to a Bayer media release, Chinese National Medical Products Administration (NMPA) has approved Xofigo(radium-223 dichloride) for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastases. The approval of Xofigo in China is based on the ALSYMPCA data as well as the NCT01810770 trial operated in Asia.
- 01 Nov 2017 Status changed from active, no longer recruiting to completed.
- 13 Jul 2016 Status changed from recruiting to active, no longer recruiting.